514 related articles for article (PubMed ID: 21761950)
1. Cost and utilization outcomes of opioid-dependence treatments.
Baser O; Chalk M; Fiellin DA; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S235-48. PubMed ID: 21761950
[TBL] [Abstract][Full Text] [Related]
2. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Baser O; Chalk M; Rawson R; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
[TBL] [Abstract][Full Text] [Related]
3. Utilization patterns of extended-release naltrexone for alcohol dependence.
Jan S; Gill P; Borawala AS
Am J Manag Care; 2011 Jun; 17 Suppl 8():S210-2. PubMed ID: 21761946
[TBL] [Abstract][Full Text] [Related]
4. Healthcare utilization and costs associated with treatment for opioid dependence.
Shah A; Duncan M; Atreja N; Tai KS; Gore M
J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
[TBL] [Abstract][Full Text] [Related]
5. Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization.
Bryson WC; McConnell J; Korthuis PT; McCarty D
Am J Manag Care; 2011 Jun; 17 Suppl 8(Suppl 8):S222-34. PubMed ID: 21761949
[TBL] [Abstract][Full Text] [Related]
6. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
Hartung DM; McCarty D; Fu R; Wiest K; Chalk M; Gastfriend DR
J Subst Abuse Treat; 2014 Aug; 47(2):113-21. PubMed ID: 24854219
[TBL] [Abstract][Full Text] [Related]
7. Comparison of healthcare utilization among patients treated with alcoholism medications.
Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
[TBL] [Abstract][Full Text] [Related]
8. Healthcare costs and nonadherence among chronic opioid users.
Leider HL; Dhaliwal J; Davis EJ; Kulakodlu M; Buikema AR
Am J Manag Care; 2011 Jan; 17(1):32-40. PubMed ID: 21348566
[TBL] [Abstract][Full Text] [Related]
9. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
10. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
[TBL] [Abstract][Full Text] [Related]
11. Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Rathlev N; Lee JD; Gordon M; Nunes EV; O'Brien CP; Friedmann PD
J Subst Abuse Treat; 2018 Feb; 85():66-69. PubMed ID: 28576389
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
Mannelli P; Patkar AA; Peindl K; Murray HW; Wu LT; Hubbard R
J Clin Psychopharmacol; 2007 Oct; 27(5):468-74. PubMed ID: 17873678
[TBL] [Abstract][Full Text] [Related]
13. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
Saxon AJ; Akerman SC; Liu CC; Sullivan MA; Silverman BL; Vocci FJ
Addiction; 2018 Aug; 113(8):1477-1487. PubMed ID: 29493836
[TBL] [Abstract][Full Text] [Related]
14. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
Jackson J; Fernandes AW; Nelson W
Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
[TBL] [Abstract][Full Text] [Related]
15. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility.
Fishman MJ; Winstanley EL; Curran E; Garrett S; Subramaniam G
Addiction; 2010 Sep; 105(9):1669-76. PubMed ID: 20626723
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
Jackson H; Mandell K; Johnson K; Chatterjee D; Vanness DJ
Subst Abus; 2015; 36(2):226-31. PubMed ID: 25775099
[TBL] [Abstract][Full Text] [Related]
17. Costs associated with attempted suicide among individuals with bipolar disorder.
Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
[TBL] [Abstract][Full Text] [Related]
18. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
[TBL] [Abstract][Full Text] [Related]
19. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
Murphy SM; Jeng PJ; McCollister KE; Leff JA; Jalali A; Shulman M; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
Addiction; 2021 Dec; 116(12):3444-3453. PubMed ID: 33950535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
